Chinese
Japan
English
Explore In Vivo CAR-T Resources in One Convenient Hub
White papers | Posters | Videos
Start Your In Vivo CAR-T Journey Now!
In vivo CAR-T is reshaping cell therapy by enabling direct immune cell engineering inside the patient, eliminating complex ex vivo steps such as cell extraction, modification, and reinfusion. This streamlined approach improves speed, scalability, and cost efficiency. With flexible delivery options, including RNA-LNP and viral vector technologies, in vivo CAR-T is opening a new path toward truly scalable cell therapies.
This resource hub brings together expert insights, technical content, and platform capabilities to support your in vivo CAR-T journey—from discovery to delivery.
In Vivo CAR-T Discovery
Build a strong foundation with optimized CAR design, antibody selection, and early-stage validation strategies.
What You’ll Learn
Strategies for CAR construct optimization
Antibody screening and lead identification
Key considerations for in vivo functionality
Antibody CMC for In Vivo CAR-T
Ensure robust and scalable antibody fragment production with tailored CMC strategies for in vivo applications.
Cell line development for antibody fragments
Upstream and downstream process optimization
Quality and consistency in biologics manufacturing
Plasmid DNA for In Vivo CAR-T
High-quality plasmid DNA is critical for both viral and non-viral delivery pathways.
Multiple linearized DNA options
Critical quality attributes for plasmid design
Poly(A) sequence control and its impact on expression
RNA-tLNP Delivery Pathway
Enable targeted, non-viral delivery of CAR constructs through advanced RNA-tLNP systems.
mRNA & circRNA strategies in in vivo CAR-T
LNP formulation & conjugation strategies and CMC considerations
Transient expression and safety advantages
Targeted Lentiviral Vector (tLVV) Delivery Pathway
Leverage targeted lentiviral vectors (tLVV) for efficient and durable in vivo gene delivery.
Lentiviral vector design for in vivo targeting
Packaging system, producer cell line and scalability considerations
Regulatory and safety perspectives
Explore Our In Vivo CAR-T Facility
Why Choose Us for In Vivo CAR-T?
End-to-End Platform: Discovery to GMP manufacturing
Multi-Modal Expertise: Antibody, plasmid, RNA, LNP, and viral vector
Speed & Scalability: Designed for rapid clinical translation
Global CDMO Experience: Supporting innovative cell and gene therapies worldwide
* I agree to the Terms of Use and Privacy Policy
I agree to receive the latest news, information, promotions, webinars and services, and acknowledge that I can opt out any time.